High-grade serous carcinoma (HGSC) is the most common ovarian cancer subtype. Majority of the HGSC patients experience disease recurrence and treatment resistance, leading to a poor five-year survival of <40%. We and others have shown that there are surprisingly few genomic events that drive poor response to chemotherapies, suggesting the importance of dynamic epigenetic alterations for the disease outcome.

DYNAMITE is based on a hypothesis that distinct cellular states controlled by specific transcription factors (TF) underlie the development of chemoresistance in ovarian cancer. The goal is to identify effective personalized medicine targets by dissecting the mechanistic role of defined TFs in HGSC chemoresistance and to validate the targets in pre-clinical setting with patient-derived organoids.